82 related articles for article (PubMed ID: 20379752)
21. Peptide length-based prediction of peptide-MHC class II binding.
Chang ST; Ghosh D; Kirschner DE; Linderman JJ
Bioinformatics; 2006 Nov; 22(22):2761-7. PubMed ID: 17000752
[TBL] [Abstract][Full Text] [Related]
22. POPI: predicting immunogenicity of MHC class I binding peptides by mining informative physicochemical properties.
Tung CW; Ho SY
Bioinformatics; 2007 Apr; 23(8):942-9. PubMed ID: 17384427
[TBL] [Abstract][Full Text] [Related]
23. Peptide binding to MHC class I and II proteins: new avenues from new methods.
Yaneva R; Schneeweiss C; Zacharias M; Springer S
Mol Immunol; 2010 Jan; 47(4):649-57. PubMed ID: 19910050
[TBL] [Abstract][Full Text] [Related]
24. Selecting informative data for developing peptide-MHC binding predictors using a query by committee approach.
Christensen JK; Lamberth K; Nielsen M; Lundegaard C; Worning P; Lauemøller SL; Buus S; Brunak S; Lund O
Neural Comput; 2003 Dec; 15(12):2931-42. PubMed ID: 14629874
[TBL] [Abstract][Full Text] [Related]
25. HLA class I epitope discovery in type 1 diabetes.
van Endert P; Hassainya Y; Lindo V; Bach JM; Blancou P; Lemonnier F; Mallone R
Ann N Y Acad Sci; 2006 Oct; 1079():190-7. PubMed ID: 17130554
[TBL] [Abstract][Full Text] [Related]
26. [Analysis of peptides associated with class II MHC molecules, HLA-DR3: implication for the prediction of peptides useful for vaccines].
Georges B; Gras-Masse H; Maes P; Capron A; Tartar A; Auriault C
C R Acad Sci III; 1996 Dec; 319(12):1119-25. PubMed ID: 9091183
[TBL] [Abstract][Full Text] [Related]
27. Challenges in the use of in silico tools for predicting peptides binding to HLA-class II molecules of HCV E1, E2, and P7.
Dormer A; Pauleus CV; Syverin MN; Dacil C; Smile PG
In Silico Biol; 2009; 9(5-6):391-406. PubMed ID: 22430440
[TBL] [Abstract][Full Text] [Related]
28. Pan-specific MHC class I predictors: a benchmark of HLA class I pan-specific prediction methods.
Zhang H; Lundegaard C; Nielsen M
Bioinformatics; 2009 Jan; 25(1):83-9. PubMed ID: 18996943
[TBL] [Abstract][Full Text] [Related]
29. A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction.
Mei S; Li F; Leier A; Marquez-Lago TT; Giam K; Croft NP; Akutsu T; Smith AI; Li J; Rossjohn J; Purcell AW; Song J
Brief Bioinform; 2020 Jul; 21(4):1119-1135. PubMed ID: 31204427
[TBL] [Abstract][Full Text] [Related]
30. In silico designing breast cancer peptide vaccine for binding to MHC class I and II: A molecular docking study.
Mahdavi M; Moreau V
Comput Biol Chem; 2016 Dec; 65():110-116. PubMed ID: 27816827
[TBL] [Abstract][Full Text] [Related]
31. High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets.
Shao XM; Bhattacharya R; Huang J; Sivakumar IKA; Tokheim C; Zheng L; Hirsch D; Kaminow B; Omdahl A; Bonsack M; Riemer AB; Velculescu VE; Anagnostou V; Pagel KA; Karchin R
Cancer Immunol Res; 2020 Mar; 8(3):396-408. PubMed ID: 31871119
[TBL] [Abstract][Full Text] [Related]
32. Designing of interferon-gamma inducing MHC class-II binders.
Dhanda SK; Vir P; Raghava GP
Biol Direct; 2013 Dec; 8():30. PubMed ID: 24304645
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research.
Lin HH; Ray S; Tongchusak S; Reinherz EL; Brusic V
BMC Immunol; 2008 Mar; 9():8. PubMed ID: 18366636
[TBL] [Abstract][Full Text] [Related]
34. Neural network method for predicting peptides that bind major histocompatibility complex molecules.
Gulukota K; DeLisi C
Methods Mol Biol; 2001; 156():201-9. PubMed ID: 11068761
[No Abstract] [Full Text] [Related]
35. HPLC and MS analysis for the identification and characterisation of peptides presented in the context of the non-classical human leukocytes antigen (HLA) class I molecule HLA-E.
Millo E; Damonte G
Curr Pharm Des; 2009; 15(28):3325-35. PubMed ID: 19860682
[TBL] [Abstract][Full Text] [Related]
36. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions.
Karosiene E; Lundegaard C; Lund O; Nielsen M
Immunogenetics; 2012 Mar; 64(3):177-86. PubMed ID: 22009319
[TBL] [Abstract][Full Text] [Related]
37. A Cohesive and Integrated Platform for Immunogenicity Prediction.
Dimitrov I; Atanasova M; Patronov A; Flower DR; Doytchinova I
Methods Mol Biol; 2016; 1404():761-770. PubMed ID: 27076336
[TBL] [Abstract][Full Text] [Related]
38. MATHLA: a robust framework for HLA-peptide binding prediction integrating bidirectional LSTM and multiple head attention mechanism.
Ye Y; Wang J; Xu Y; Wang Y; Pan Y; Song Q; Liu X; Wan J
BMC Bioinformatics; 2021 Jan; 22(1):7. PubMed ID: 33407098
[TBL] [Abstract][Full Text] [Related]
39. Understanding and predicting binding between human leukocyte antigens (HLAs) and peptides by network analysis.
Luo H; Ye H; Ng H; Shi L; Tong W; Mattes W; Mendrick D; Hong H
BMC Bioinformatics; 2015; 16 Suppl 13(Suppl 13):S9. PubMed ID: 26424483
[TBL] [Abstract][Full Text] [Related]
40. A web-based resource for designing therapeutics against Ebola Virus.
Dhanda SK; Chaudhary K; Gupta S; Brahmachari SK; Raghava GP
Sci Rep; 2016 Apr; 6():24782. PubMed ID: 27113850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
